P2Y12 Inhibitors in Acute Coronary Syndromes: A Real-World, Community-Based Comparison of Ischemic and Bleeding Outcomes

Table 3

Changes in medication use from index to 12-month follow-up.

Adherence	Clopidogrel (N = 14408)	Ticagrelor (N = 570)		Prasugrel (N = 501)
	Mean (SD) or N (%)	Mean (SD) or N (%)		Mean (SD) or N (%)
Adherence, mean PDC	89.3 (22.3)	89.4 (21.0)	0.06	88.1 (22.5)	0.26
Adherence, PDC >80%	11914 (82.7)	462 (81.3)	0.40	395 (78.8)	0.03
Switched drug	289 (2.0)	109 (19.2)	<0.001	64 (12.8)	<0.001
Persistence	10671 (74.1)	397 (69.9)	0.03	339 (67.7)	0.001

PDC, percent of days covered. Each of the novel P2Y12 inhibitors was compared to clopidogrel, respectively.